| Name | Title | Contact Details |
|---|
Response Genetics is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aravive, Inc., is a clinical stage biotechnology company focused on developing new therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. Our primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a critical role in multiple types of malignancies by promoting metastasis and cancer cell survival. Our technology, originated in the laboratories of Drs. Amato Giaccia and his colleagues at Stanford University, uses genetic screening to identify critical targets for the development of therapeutic molecules for cancer therapy while sparing healthy cells. This strategy is designed to enable us to interrupt oncogenic signals and, using our high-affinity decoy receptors, outcompete cancer`s ability to grow, metastasize and acquire resistance to treatments. We believe our unique cancer therapies may hold promise as a monotherapy or in combination with other cancer treatments, augmenting the anti-tumor activity of radiotherapy, chemotherapy, immuno-therapeutics and cancer vaccines. By targeting advanced or metastatic disease, our approach has the potential to significantly improve survival rates while simultaneously reducing toxicity in cancer patients.
BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano. BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements.
Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods.
"Our company`s promise is in our name - CSHM - Committed to Smiles and a Healthy Mouth. Our mission is to ensure access to quality, professional dental care for low-income, underserved families and those seeking comprehensive care. Our dental centers are creating access to dental health services for these families – and especially their children – who are often least able to afford care."